Earnings per Share (EPS) (Diluted): A company's net earnings or losses attributable to common shareholders per diluted share basis, which includes all convertible securities and debt, options and warrants.
Ultragenyx Pharmaceutical Inc. (RARE) had Earnings per Share (EPS) (Diluted) of $-1.81 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$159.93M |
|
$-180.41M |
|
$27.99M |
|
$131.94M |
|
$330.82M |
|
$-170.89M |
|
$-8.65M |
|
$-179.54M |
|
$-179.54M |
|
$-180.41M |
|
$-180.41M |
|
$-180.41M |
|
$-180.41M |
|
$-170.89M |
|
$-162.99M |
|
99.77M |
|
99.77M |
|
$-1.81 |
|
|
Earnings per Share (EPS) (Diluted) |
$-1.81 |
| Balance Sheet Financials | |
$643.21M |
|
$249.96M |
|
$547.24M |
|
$1.19B |
|
$340.02M |
|
-- |
|
$841.26M |
|
$1.18B |
|
$9.16M |
|
$-208.19M |
|
$9.16M |
|
96.44M |
|
| Cash Flow Statement Financials | |
$-366.17M |
|
$308.25M |
|
$83.81M |
|
$184.16M |
|
$214.70M |
|
$30.54M |
|
$115.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.89 |
|
-- |
|
-- |
|
-- |
|
-- |
|
82.50% |
|
-106.85% |
|
-106.85% |
|
-- |
|
-112.26% |
|
-112.81% |
|
$-371.23M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.54 |
|
1.42 |
|
63.33 |
|
-1969.82% |
|
86.66% |
|
-15.16% |
|
-1969.79% |
|
$0.10 |
|
$-3.72 |
|
$-3.67 |
|